# Signature Research Project

> **NIH NIH P50** · UNIV OF MASSACHUSETTS MED SCH WORCESTER · 2024 · $1,102,296

## Abstract

JASPR (SIGNATURE PROJECT): ABSTRACT
 Significance: The significance of this Signature Project is derived from its powerful combination of (1)
targeting a high-risk population -- adult patients at risk for suicide presenting to emergency departments (EDs);
(2) addressing trenchant barriers that have prevented delivery of suicide-related evidence-based practices
(EBPs) in the ED through an innovative, multi-component, NIMH-funded technology called Jaspr; and (3)
evaluating Jaspr’s efficacy, effectiveness, and implementation, all in the same highly efficient study.
 Investigators: Jaspr’s project team has pioneered ED systems-based suicide prevention using continuous
quality improvement implementation strategies (Boudreaux, Kiefe, Larkin, Johnson, Volturo); digital behavioral
health technology development and deployment (Boudreaux, Dimeff, Gerber); using multi-method approaches,
including patient-reported measures, electronic health record (EHR) data, and death registries, for outcome and
intervention target ascertainment (Boudreaux, Kiefe, Gerber); implementation science research design and
analytic methodologies (Kiefe, Yang, Larkin); and healthcare economics (Singh, Clements).
 Innovation: This will be the first study to comprehensively evaluate a multi-component suicide prevention
technology that facilitates delivery of suicided-related EBPs while replacing wasted waiting time with productive
time. Its multi-component nature satisfies several key performance elements for systems adopting Zero Suicide.
A novel, award-winning hybrid study design called Complementary Randomized Controlled Trial and Real-World
Study for Efficacy, Effectiveness, and Implementation Design (CREID) will be used.
 Approach: CREID comprises two separate but related components or parts. Part A, Randomized Controlled
Trial (RCT), will be a patient-level, randomized, parallel-arm, single-blind trial (n=670) comparing Jaspr
(Intervention) to enhanced treatment as usual (ETAU; Active Comparator Control). Consistent with NIMH’s
experimental therapeutics paradigm, Part A’s primary aim is to determine Jaspr’s efficacy in improving suicide-
related outcomes in the 12 months after the index ED visit and to explore its potential mechanisms of action
through engaging patient intervention targets and EBP delivery. In Part B, Real-World Study, four diverse EDs
will implement Jaspr as part of routine care. Part B’s primary aim will be to evaluate Jaspr’s effectiveness when
used in a real-world setting. Finally, both Parts will be used to explore Jaspr’s implementation, including
establishing system, clinician, and patient factors anticipated to affect Jaspr adoption and implementation.
 Environment: The UMass Chan Medical School (UMass), Jaspr Health, and partnering organizations have
proven their ability to support this ambitious study by their success with numerous NIMH-funded, systems-based
suicide prevention studies and SBIR/STTRs technology grants, including the SBIR that created J...

## Key facts

- **NIH application ID:** 10821329
- **Project number:** 5P50MH129701-02
- **Recipient organization:** UNIV OF MASSACHUSETTS MED SCH WORCESTER
- **Principal Investigator:** Edwin D Boudreaux
- **Activity code:** P50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $1,102,296
- **Award type:** 5
- **Project period:** 2023-04-05 → 2028-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10821329

## Citation

> US National Institutes of Health, RePORTER application 10821329, Signature Research Project (5P50MH129701-02). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10821329. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*